The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS.
| Autor: | Li JW; Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410000, China., Deng C; Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410000, China., Zhou XY; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Deng R; Department of Oncology, The Second Hospital of Zhuzhou City, Zhuzhou, 412000, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Heliyon [Heliyon] 2023 Dec 27; Vol. 10 (1), pp. e23921. Date of Electronic Publication: 2023 Dec 27 (Print Publication: 2024). |
| DOI: | 10.1016/j.heliyon.2023.e23921 |
| Abstrakt: | EBV positive Diffuse Large B-cell lymphoma, not otherwise specified (EBV+DLBCL-NOS) referred to DLBCL with expression of EBV encoded RNA in tumor nucleus. EBV+DLBCL-NOS patients present with more advanced clinical stages and frequent extranodal involvement. Although rituximab-containing immunochemotherapy regimens can significantly improve outcomes in patients with EBV+DLBCL, the best first-line treatment needs to be further explored. Due to the relatively low incidence and regional variation of EBV+DLBCL-NOS, knowledge about this particular subtype of lymphoma remains limited. Some signaling pathways was abnormally activated in EBV+DLBCL-NOS, including NF-κB and JAK/STAT pathways) and other signal transduction pathways. In addition, immune processes such as interferon response, antigen-presenting system and immune checkpoint molecule abnormalities were also observed. Currently, chimeric antigen receptor T-cell (CAR-T) therapy, chemotherapy combined with immunotherapy and novel targeted therapeutic drugs are expected to improve the prognosis of EBV+DLBCL-NOS patients, but more studies are needed to confirm this. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2023 The Authors. Published by Elsevier Ltd.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|